AI Drug Discovery for Pharma and Biotech

Drug discovery

1

drug

With orphan designation

Overview

Large congenital melanocytic nevus (LCMN) is a rare congenital pigmented lesion (>20 cm projected adult size) caused by somatic NRAS or BRAF mutations, presenting a 2-10% lifetime risk of melanoma and potential neurocutaneous melanocytosis (NCM) [1][4][16]. Diagnosis is clinical, supported by imaging for neurological complications. Management emphasizes surveillance, psychosocial support, and selective surgical intervention [1][8][13].

Population

  • Incidence: 1/20,000 to 1/50,000 births, with giant CMN (>40 cm) occurring in 1/50,000–1/500,000 [1][4][9].

  • Affects all ethnicities equally, with slight female predominance [1][16].

  • Neurological involvement (NCM) occurs in 5–15% of large/giant CMN cases [7][16].

Burden

  • Oncologic: 2–10% risk of melanoma (cutaneous or CNS), with ≤70% mortality in metastatic cases [1][2][5].

  • Neurological: Symptomatic NCM carries >50% mortality within 3 years of diagnosis [3][5][16].

  • Psychosocial: Significant stigma from disfigurement, requiring lifelong psychological support [5][8][16].

Therapies

  • Surgical excision: Primary approach for cosmetic improvement or symptomatic lesions, though prophylactic removal does not eliminate melanoma risk [5][8][16].

  • Laser therapy/dermabrasion: Reduces pigmentation but has high recurrence rates; often adjunctive [8][13].

  • Investigational therapies: NRAS/BRAF inhibitors, gene editing, and immunotherapy under study [3][4][18].

Categories: rare genetic diseases, rare neoplastic diseases, rare skin diseases

Research Papers

411 drug discovery papers about Large congenital melanocytic nevus. Recent publications:

411 drug discovery papers about Large congenital melanocytic nevus. Recent publications:

categories:

Small molecules

small molecules
2026-06-23 | ID #138 Extramedullary Intradural Spinal Tumor in Infant with Neurocutaneous Melanosis

Abstract Neurocutaneous Melanosis (NCM) is a developmental disorder of melanocytic precursors resulting in an exceedingly rare disorder characterized by the presence of melanocytic nevi in the skin and leptomeninges. NCM diagnosis is traditionally made by the presence of large, pigmented congenital nevi in association with meningeal melanosis. The occurrence of intraspinal tumors are rarely reported. We describe the first case of a neonate diagnosed with NCM at birth who was concomitantly found to have a compressive, extramedullary, intradural NCM spinal tumor with leptomeningeal involvement. A full-term infant born at 39 weeks was noted at birth to have a giant melanocytic nevus with innumerable satellite nevi and diagnosed with NCM. MRI showed hyperintense areas on T1-weighted sequences consistent with melanin deposition in the brain and an enhancing mass in the spine from T10-T12 without hydrocephalus. After 3 weeks of life, the patient experienced obstructive hydrocephalus from leptomeningeal dissemination in the pons and upper cervical cord. A palliative VP shunt was placed. At 9 months of age, the patient presented with clinical signs of spinal cord dysfunction including mild axial hypotonia, increased peripheral tone, brisk suprapatellar reflexes, and difficulty bearing weight when lifted in vertical position. A T8-T12 laminoplasty for resection of the extramedullary spinal tumor was performed. Pathology revealed spindle cell neoplasm. At 4-months follow-up, there was no sign of recurrent mass in the spine, but leptomeningeal enhancement around the brain stem and cranial nerves remained. Exome sequencing of the resected tumor revealed two somatic cancer-associated sequence variants of NRAS and RAF1. Although the presence of an activating missense mutation in NRAS supports the diagnosis of NCM and has been previously described in NCM, RAF1 missense mutation is a novel variant identified in this patient. Novel insights from this case may provide important opportunities for targeted therapeutic intervention for infants with NCM.

Open article ↗



2026-05-03 | MC1R-Targeted Apoptotic Induction Followed by Melanocyte Stem Cell Transplantation: A Novel Therapeutic Strategy for Giant Congenital Melanocytic Nevus

Description: Giant Congenital Melanocytic Nevus (GCMN) is a rare congenital condition characterized by aberrant melanocyte proliferation affecting large areas of skin, including the face, with no current treatment achieving complete, safe resolution. This hypothesis proposes a three-stage targeted therapeutic strategy: Stage 1: A designed conjugate molecule (NDP-MSH + pH-sensitive linker + BH3 mimetic) selectively eliminates GCMN melanocytes via MC1R-mediated endocytosis and apoptotic induction — without affecting surrounding keratinocytes, nerve fibers, or vascular structures. Stage 2: Image-guided delivery using Line-field Confocal Optical Coherence Tomography (LC-OCT) ensures cellular-precision targeting at the dermal-epidermal junction. Stage 3: Autologous melanocyte stem cell transplantation repopulates the cleared niche with normally functioning melanocytes, restoring physiological pigmentation. This approach is supported by recent evidence confirming BCL2 overexpression in GCMN cells, and by established clinical outcomes in melanocyte transplantation for vitiligo

Open article ↗



2026-02-26 | Multilineage differentiation drives hamartoma formation in large-to-giant congenital melanocytic naevi: evidence for naevocyte multipotency.

Large-to-giant congenital melanocytic naevi (LGCMNs) often develop nodules that contain ectopic tissues (hamartomas), which are rarely observed in small-to-medium congenital melanocytic naevi (SMCMNs). The origin and mechanism of the hamartomas formed in LGCMNs remain unknown. To investigate the origin and mechanism of hamartoma formation in LGCMNs, and to evaluate the stemness and multipotency of LGCMNs. A total of 276 congenital melanocytic naevi (CMNs) of different sizes were included in this study. LGCMNs with diverse hamartomas were identified and analysed by histology and immunofluorescence. Whole-exome sequencing (WES) of matched healthy skin, LGCMN and hamartoma tissues assessed mutational overlap. RNA sequencing (RNAseq), immunohistochemistry and immunocytochemistry evaluated multipotency pathways and stem markers across CMN sizes. LGCMN and SMCMN cells were assayed for clonogenicity and induced to differentiate along osteogenic, chondrogenic, adipogenic and neurogenic lineages in vitro. Three-dimensional spheroid cultures and cell-derived xenograft (CDX) models tested LGCMN multilineage differentiation in vivo. Single-cell RNAseq (scRNAseq) of patient-derived hamartomas delineated intermediate differentiation states and active pathways. We found that LGCMN lesions harboured bone, cartilage, adipose and neural hamartomas with intermixed naevocytes. WES revealed 35-92% overlap of somatic mutations (including driver mutations) between LGCMN and hamartoma tissue, indicating a common origin. Immunofluorescence identified cells in hamartoma co-expressing lineage-specific and naevocyte markers, indicating intermediate differentiation states. RNAseq, immunohistochemistry and immunocytochemistry showed that LGCMNs were enriched for multipotency pathways and expressed higher levels of stem cell markers than SMCMNs. LGCMNs showed greater clonogenicity in vitro, and all LGCMNs robustly differentiated into osteocytes, chondrocytes, adipocytes and neuronal cells/astrocytes, whereas SMCMNs or healthy melanocytes largely failed. Intriguingly, in three-dimensional cultures and CDX models, LGCMNs were able to form lineage-specific hamartomas. scRNAseq identified intermediate differentiation clusters that co-expressed melanocytic and multilineage markers, confirming the transdifferentiation. Upregulation of neuroactive ligand-receptor signalling was identified as the common feature during differentiation. Hamartomas in LGCMNs originate from the LGCMN cells themselves, which undergo multipotent differentiation. LGCMNs have markedly greater stemness and multipotency than SMCMNs. Our data implicate the neuroactive ligand-receptor pathway in mediating LGCMN transdifferentiation. These findings shed light on LGCMN development and suggest that modulating differentiation pathways might offer new therapeutic approaches.

Open article ↗



2026-01-01 | Emerging Molecular Therapies for Large and Giant Congenital Melanocytic Nevi: Current Evidence and Translational Challenges

Large and giant congenital melanocytic nevi (L/GCMN) are rare mosaic disorders driven mainly by postzygotic activation of rat sarcoma viral oncogene homolog (RAS)/mitogen-activated protein kinase (MAPK) signaling. This narrative review compares emerging molecular therapies by model, biological effect, outcome, translational stage, and durability. Human evidence is limited to uncontrolled case reports and small series. Mitogen-activated protein kinase kinase (MEK) inhibitors have produced symptom relief, pigment lightening, and reduced hyperproliferative bulk, particularly in some fusiondriven lesions, but no clinical report has shown clearance of the congenital nevus or a durable response after withdrawal. An anaplastic lymphoma kinase inhibitor reduced lesion bulk in one genotypematched case. All other strategies remain preclinical. In primary cells, human explants, patient-derived xenografts, or animal models, allele-specific silencing of mutant neuroblastoma RAS viral oncogene homolog (NRAS), inhibition of B-cell lymphoma 2 (BCL2), phosphoinositide 3-kinase–protein kinase B (PI3K–AKT) blockade, immune activation, and histone deacetylase inhibition have produced effects ranging from pathway suppression to apoptosis or nevus-cell loss. These models are not directly comparable, and most findings await independent replication. Pigmentation, lesion dimensions, histologic markers, and mutant-cell burden measure different outcomes. Future studies should define the intended treatment goal, measure clinical and biological endpoints separately, and include follow-up after planned withdrawal. Local or intermittent delivery may reduce cumulative exposure in cutaneous L/GCMN. Combinations of complementary mechanisms warrant further preclinical study. Establishing whether treatment suppresses the nevus phenotype or removes nevus cells, at an exposure acceptable for children, is likely to matter more than adding molecular targets.

Open article ↗



2025-11-28 | Amelanotic melanoma of the central nervous system with systemic spread - imaging pitfalls and clues in a rare paediatric case with congenital melanocytic naevi.

Amelanotic melanoma involving the central nervous system (CNS) in association with congenital melanocytic naevi (CMN) is exceptionally rare and aggressive. Our literature review identified only two prior paediatric cases, reported in 1999 and 2021. To the best of our knowledge, this is the first reported paediatric case of CNS amelanotic melanoma with systemic metastases associated with CMN. We present a 2-year-old girl with CMN who developed an afebrile seizure, vomiting and neurological decline. Imaging revealed hydrocephalus, diffuse leptomeningeal enhancement, spinal cord compression and distant metastases. Histopathology confirmed metastatic amelanotic melanoma. She was treated with targeted therapy comprising trametinib and azacitidine, with a plan for immunotherapy (nivolumab and ipilimumab) after weaning off intravenous dexamethasone for cord compression. This case underscores the diagnostic challenge due to imaging similarities with other neoplastic, infectious and inflammatory pathologies. Given the aggressive nature and poor prognosis, a high index of suspicion should be raised for melanoma in patients with CMN and neurocutaneous melanosis who develop progressive neurological symptoms.

Open article ↗



cell therapies
2026-01-01 | Advances in the Treatment of Congenital Giant Nevi with Artificial Dermis

Congenital melanocytic nevus (CMN) is a common congenital pigmented skin lesion, and giant CMN remains challenging in reconstructive surgery because of the large defect after resection.Conventional approaches such as flaps and autologous skin grafting are limited by donor-site morbidity, multiple operations and obvious scar contracture.Artificial dermis, as a dermal substitute, provides a three-dimensional scaffold that promotes vascularization and dermal regeneration, and has been

Open article ↗



2024-03-10 | Superficial Temporal Artery Island Flap Combined With Laser Hair Removal for Inadequate Skin Expansion Following Tissue Expansion: A Case Report of Congenital Melanocytic Nevus of the Forehead in an Adult

Tissue expansion is a handy reconstructive technique for the head and neck region; however, its implementation requires careful planning and surgical experience. If tissue expansion is inadequate, forced closure results in wound tension and risks complications, such as postoperative deformity, wide scarring, and wound dehiscence. We report a case of adult forehead melanocytic nevus excision using a tissue expander (TE) where complications caused by insufficient tissue expansion were avoided by creating a flap using a dog ear. The patient was a male in his 20s who underwent surgery with a TE for a congenital melanocytic nevus sized 15 × 10 cm on the left forehead. Resection was performed by tissue expansion using two TEs; however, simple advancement flaps led to excessive wound tension, risk of elevation of the eyebrow on the affected side, and postoperative scarring. Hence, a superficial temporal artery fasciocutaneous island flap with left superficial temporal vessels as a pedicle was raised at the dog ear and moved to the site of strong tension, and the wound was closed without difficulty. Although postoperative laser hair removal was required, both the appearance and functional results were satisfactory. Using anatomical flaps obtained from the surroundings during tissue expansion helps avoid complications associated with forced wound closure.

Open article ↗



2023-10-30 | Reconstruction of a medium-sized congenital melanocytic nevus defect using a thin thoracodorsal artery perforator free flap: a case report

Congenital melanocytic nevus (CMN) is a benign condition that either is present at birth or develops in the first weeks of life. Surgical removal is typically performed to improve cosmetic appearance and reduce the risk of malignant transformation. In this report, we present the case of a 26-year-old woman with a medium-sized CMN on her left breast. The nevus measured 14×8 cm, and the patient desired a single-stage excision. However, this approach would result in a large skin defect that would be challenging to reconstruct using a local flap or skin graft. Moreover, it could potentially compromise the maintenance of natural sagging and the contour of the breast. Consequently, we opted to place a thin thoracodorsal artery perforator free flap following the removal of the CMN. The patient was satisfied with the overall surgical results. By utilizing this free flap for reconstruction, we successfully preserved the natural shape and contour of the breast without complications such as postoperative hypertrophic scarring or contracture at the recipient site.

Open article ↗



2022-05-01 | Keratinocyte Culture: Siriraj’s Experience

Objective: Cell-based therapy is gaining increasing prominence in medicine, where it has the potential to replace or repair damaged tissue using new engineered cells. Skin cell engineering, also known as keratinocyte culture or cultured epithelial autograft (CEA), is a promising field in cell-based therapy. CEA is now used in many parts of the world as an alternative treatment for some diseases that require large defects to be covered, such as severe and major burn patients and congenital melanocytic nevus. The use of CEA in conjunction with acellular skin substitution is rapidly expanding.Materials and Methods: This study is an initiative aimed at supporting the production and use of keratinocyte cultures at Siriraj Hospital. This is the first stage of developing sheet keratinocyte culture in vitro.Results: Our study yielded very promising results. As feeder cells, we used irradiated 3T3 murine fibroblasts, as per the standard protocol for keratinocyte culture. The growth duration was four weeks: 2 weeks for the 3T3 murine fibroblasts and 2 weeks for the keratinocytes. The keratinocytes grew rapidly and formed sheets with irradiated 3T3 murine fibroblasts. The retrieval of the cell sheets was straightforward thanks to the temperature-response cell culture dish and halo-ring cell recovery sheet. Flow cytometry revealed that the cells had a very high viability and purity. H&E staining revealed the sheets comprised two to four layers of stratified epithelial tissue.Conclusion: From this study, our method of manufacturing the CEA can offer a promising result. This can be use in the treatment which require large skin coverage. However, we aim to initiate animal and human trial phase next.

Open article ↗



2021-01-26 | Clinical Analysis of Cultured Epidermal Autograft (JACE) Transplantation for Giant Congenital Melanocytic Nevus

Cultured epidermal transplantation (JACE) is performed for giant congenital melanocytic nevus (GCMN), but there are few reports on its postoperative course and surgical content or indications. We aimed to investigate the postoperative course of GCMN patients undergoing cultured epidermal autograft transplantation and compare the outcomes between 2 nevus tissue resection methods.Twelve GCMN patients aged 0 months to 8 years and 9 months were included in this single-center case series study. Cultured epidermal autograft transplantation was performed at 19 sites of the patients' extremities and trunks, after excision of the nevus either by using an electric dermatome, which we initially used in 2017, or by curettage with a sharp spoon and use of a hydrosurgery system (Versajet), which we started performing in 2018. Univariate and multivariate analyses were performed for factors associated with postoperative hypertrophic scar formation.In all cases, >90% of the grafts survived, and the dark brown color of the nevus was reduced. Average postoperative observation period was 16.5 months. Hypertrophic scar formation was observed postoperatively at 9 wound sites out of the 12 sites with GCMN removed with a dermatome and at only 1 site with GCMN removed by curettage with use of a hydrosurgery system. In the univariate and multivariate analyses, hypertrophic scar formation was associated with age at surgery.In cultured epidermal autograft transplantation for GCMN, nevus tissue removal at an early age by curettage with use of a hydrosurgery system can provide good results while reducing complications, including recurrence and hypertrophic scar formation.

Open article ↗



antibodies
2025-11-25 | Epigenomic characterization and therapeutic challenges of melanoma arising in giant nevi in pediatric patients

BACKGROUND: Congenital giant melanocytic nevi (CGMN) are rare melanocytic proliferations present at birth, associated with an increased risk of pediatric malignant melanoma (MM). Melanomas arising within CGMN are uncommon but clinically aggressive, with diagnostic challenges due to overlapping histopathological features with benign proliferations. This case series explores the clinicopathologic, molecular, and therapeutic profiles of three pediatric patients with MM arising in CGMN. METHODS: An integrated analysis-including histopathology, immunohistochemistry, mutational profiling (NRAS, BRAF, PRKAR1A), copy number variation (CNV) analysis, and DNA methylation profiling using the classifier developed at the German Cancer Research Center (DFKZ) in Heidelberg-was performed on tumor and matched nevus samples. RESULTS: All tumors harbored MAPK pathway alterations, including NRAS Q61 mutations or BRAF fusions. DNA methylation profiling confirmed malignant transformation, while matched nevi clustered as melanocytoma with flat CNV profiles. Immunotherapy with checkpoint inhibitors (nivolumab ± ipilimumab) was used in all cases despite low PD-1/PD-L1 expression. However, therapeutic response was inconsistent, and two patients developed severe immune-related hepatitis requiring treatment discontinuation. Only one patient remains in remission. Epigenomic analyses revealed that benign and malignant components shared a close clustering pattern, suggesting a common cellular origin and patient-specific epigenetic imprinting. CONCLUSION: MM arising within CGMN poses diagnostic and therapeutic challenges. While molecular and epigenomic profiling supports accurate classification and understanding of disease biology, the role of immunotherapy remains uncertain-marked by reduced efficacy and significant immune-related toxicity. A multidisciplinary approach is essential to guide management and improve outcomes in this rare pediatric malignancy.

Open article ↗



2018-11-01 | RARE-03. CHARACTERISTICS OF PATIENTS WITH NEUROCUTANEOUS MELANOSIS: THE MSK EXPERIENCE FROM 2003–2018

The incidence of large congenital melanocytic nevi (LCMN) is 1/20,000 with 25% of children diagnosed with neurocutaneous melanocytosis (NCM), characterized by excessive proliferation of melanocytes in the leptomeninges and brain parenchyma. Specifically the disorder represents abnormal migration of melanocyte precursors due to abnormal melanin-producing genes in primitive leptomeningeal cells. While NCM can transform to melanoma, the molecular drivers involved in NCM related melanoma are different from the drivers in patients with non-NCM related melanoma. Children who become symptomatic from NCM may have a poor prognosis overall with 25–60% developing melanoma. While melanoma typically harbors mutations in the BRAF gene, NCM has a distinct molecular signature comprised primarily of mutations in the NRAS gene. We reviewed our institutional database from 2003–2018 and identified 47 patients with large congenital melanocytic nevi (LCMN) and NCM. Fifteen were female and 16/47 died. Five had molecular testing which revealed an NRAS mutation in the affected tissues. Four patients who developed melanoma, received targeted therapy including off label trametinib, nivolumab and/or ipilumumab. While none of these patient were longterm survivors, one patient lived for 12 months after receiving radiation therapy, nivolumab and ipilumumab. One patient with a VP shunt developed intraperitoneal melanoma, malignant ascites and subsequently died. CONCLUSIONS: While NCM which transforms to melanoma is typically fatal, new targeted therapies may offer prolonged survival. Further efforts to identify which patients are high risk are needed in an attempt to offer earlier treatment.

Open article ↗



2005-11-22 | Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma.

Glypican-3 (GPC3) mRNA and protein are expressed in >80% of human hepatocellular carcinomas (HCC) but not in normal tissues except for placenta and fetal liver. The oncofetal antigen GPC3 is a glycosylphosphatidyl inositol-anchored membrane protein and may be secreted. It is a novel tumor marker for human HCC: GPC3 protein was present in sera from 40-50% of HCC patients, but was not detected in sera from patients with liver cirrhosis or chronic hepatitis, or in sera from healthy individuals. alpha-Fetoprotein (AFP) and PIVKA-II (protein induced by vitamin K absence or antagonist-II), are well known major tumor markers for HCC. Generally, AFP shows high positivity for HCC but also high false-positivity in detection assays. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) is a recently described marker of HCC. Detection of AFP-L3 shows a much higher specificity than AFP, but a lower sensitivity. On the other hand, detection of PIVKA-II shows a lower false-positivity, but is not always sensitive enough to detect low levels secreted by small HCCs. There was no correlation between the three tumor markers, AFP, PIVKA-II, and GPC3 in terms of their presence in HCC cells. All three tumor markers showed similar positivity in patients with HCC, detecting 80% of patients with the disease. GPC3 is also a novel tumor marker for the diagnosis of human melanoma, especially in the early stages of the disease. Expression of GPC3 mRNA and protein was evident in tumor cells from >80% of patients with melanoma and melanocytic nevus, which is a common benign lesion. GPC3 protein was detected in sera from 40% (36/91) of melanoma patients, but not in sera from those with large congenital melanocytic nevus, or from healthy donors. Surprisingly, we detected serum GPC3 even in patients with stage 0, in situ melanoma. The positive detection rate of serum GPC3 at stage 0, I, and II (44.4%, 40.0%, 47.6%, respectively) was significantly higher than that of 5-S-cysteinyldopa, a well known tumor marker for melanoma (0.0%, 8.0%, and 10.0%, respectively). Interestingly, GPC3 was highly immunogenic in mice and elicited effective anti-tumor immunity with no evidence of autoimmunity. Thus, GPC3 is useful for diagnosis of HCC and melanoma and may also have a role in immunotherapy or tumor prevention. However, studies in humans are warranted.

Open article ↗



proteins
2026-01-06 | Melanomas and Mesenchymal Tumors Arising in Giant Congenital Melanocytic Nevi: Clinico-Pathological and Molecular Characterization of a Case Series.

Giant congenital melanocytic nevi (GCMN) are benign mosaic disorders that may give rise to various tumor types through incompletely understood mechanisms. We characterized a series of two melanomas and four mesenchymal tumors (two embryonal rhabdomyosarcomas, one small round cell sarcoma, one low-grade mesenchymal tumor) arising in GCMN. Median onset age was 3.5 years and 3 months for melanoma and mesenchymal tumor patients, respectively. Both melanoma patients succumbed within 27 months from diagnosis, whereas no patients progressed in the mesenchymal group (median follow-up 46 months). NRAS Q61, BRAF V600E mutation, and a novel in frame BIN1::BRAF fusion were detected in four, one, and one cases, respectively, with a higher variant allele frequency in the tumors compared with the matched GCMN. Copy number alterations and/or copy-neutral loss of heterozygosity were exclusively found in the tumors in all cases. An inactivating ASXL1 variant and an in-frame KDM5B::LPGAT1 fusion were identified in one melanoma; paternal disomy of 11p15.5 in both embryonal rhabdomyosarcomas. Mesenchymal tumors and melanomas showed distinct transcriptional profiles enriched in muscle and synapse organization and epidermal differentiation genes, respectively.

Open article ↗



2025-10-01 | Utility of Clinical and Dermoscopic Study of Cutaneous Nevi

Abstract Background: Dermoscopy is a noninvasive diagnostic tool that enhances the visualization of subsurface skin structures, enabling the differentiation of various types of nevi. Aims and Objectives: To assess the clinical features and dermoscopic patterns of cutaneous nevi. Materials and Methods: This cross-sectional study involved 100 patients presenting with nevi at a tertiary care dermatology outpatient clinic over 21 months. Demographic and clinical data were collected, and lesions were examined using a polarized, noncontact dermoscope (ILLUCO IDS-1100) connected to a smartphone. Dermoscopic images were analyzed for pattern types. Results: Participants ranged in age from 1 to 70 years (mean age 32.8 ± 14.3), with females making up 59% of the sample. The most common site of lesions was the cheek, followed by the back and chin. Compound melanocytic nevi were the most prevalent (57%), followed by junctional melanocytic nevi (14%), congenital melanocytic nevi (6%), and intradermal melanocytic nevi (6%). Less common types included Becker’s nevus, linear verrucous epidermal nevus, nevus depigmentosus, and port-wine stains. Dermoscopic analysis showed homogeneous patterns in 61% of cases, globular in 22%, reticular in 5%, cobblestone in 3%, structureless in 3%, papillary in 2%, blotchy in 2%, and dot patterns in 1%. Follicular openings were observed in 65% of lesions. Dermoscopic patterns varied according to the type of nevus. Conclusion: Dermoscopy facilitates rapid pattern recognition and enhances the accuracy of nevi classification. Additional large-scale, multicenter studies with histopathological correlation are recommended to confirm these findings.

Open article ↗



2024-11-28 | Dermatoscopic findings of giant congenital melanocytic nevus with palmoplantar involvement: A case report

Congenital melanocytic nevi (CMN) are melanocytic nevi defined by their presence at birth or in the first few weeks of life. A giant congenital melanocytic nevus (GCMN) is usually defined as a melanocytic lesion present at birth that will reach a diameter ≥20 cm in adulthood. Despite its rarity, this lesion is important because it may be associated with severe complications, such as malignant melanoma, which can affect the central nervous system (neurocutaneous melanosis) and can have a major psychosocial impact on the patient and his family due to its unsightly appearance. Herein, we present a case report of GCMN in an 18-year-old male involving the palms and soles.

Open article ↗



2024-09-02 | Title: Investigating Spontaneous Regression in Large Congenital Melanocytic Nevus: A Single-Cell Transcriptomic Study

Background Large congenital melanocytic nevus (LCMN) is a lifelong and potentially malignant skin melanocytic tumor. Case reports have documented spontaneous hypopigmentation of congenital melanocytic nevi, with histological evidence of immune cell infiltration in the lesions. Objective To explore the mechanism behind the spontaneous regression of LCMN. Methods Using Sanger sequencing and 10x Genomics single-cell RNA sequencing technology, we analyzed the genotype and cell population transformations during the spontaneous regression of LCMN. Results Our findings highlight the pivotal role of IFN-II in regressing LCMN by reversing immune evasion. IFN-II stimulates melanocytes, enhancing their antigen presentation function to recruit cytotoxic immune cells. Endothelial cells and fibroblasts further amplify the inflammatory response and help reconstruct the tumor microenvironment. The regressed LCMN displayed a marked reduction in melanocytes, increased immune cell infiltration, and remodeling of the tumor microenvironment, characterized by angiogenesis and fibroblast activity. Conclusion This study is the first to apply single-cell RNA sequencing technology to LCMN. Our unique sample provides novel insights into the tumor microenvironment of LCMN and its immune mechanisms, offering potential avenues for immunotherapy. Our findings suggest that IFN-II therapy, TIL therapy, and DC immunotherapy could be promising treatment options for LCMN, pending further validation in larger patient cohorts and transgenic animal models.

Open article ↗



2022-10-25 | OPN3 Regulates Melanogenesis in Human Congenital Melanocytic Nevus Cells through Functional Interaction with BRAFV600E.

OPN3, as a member of the opsin family, has various nonlight-dependent functions. Congenital melanocytic nevus (CMN) is a skin lesion with dark pigmentation that appears at birth and can be initiated by the BRAFV600E mutation in melanocytes. However, the role of OPN3 in BRAFV600E CMN cell melanogenesis has never been reported. In this study, we show that OPN3 acts as a negative regulator of melanin production by modulating BRAFV600E signaling in BRAFV600E CMN cells. Knocking down OPN3 expression can inhibit the BRAFV600E/extracellular signal‒regulated kinase signaling pathway and upregulate the expression of microcephaly-related transcription factors, tyrosinase, and TRP1 and TRP2, thus increasing melanin levels in BRAFV600E CMN cells. More remarkably, OPN3 and BRAFV600E were found to form a physical complex. Furthermore, a three-dimensional nevus model was used to further prove the negative regulatory effect of OPN3 on BRAFV600E CMN cell melanogenesis. Our study reveals a mechanism for OPN3-mediated melanogenesis in BRAFV600E CMN cells, and these results may lead to a more personalized and economically viable approach to treating BRAFV600E CMN.

Open article ↗



other
2026-06-23 | Mitotic Proliferative Nodule Within a Giant Congenital Nevus: One Case Report and Updated Review

Proliferative nodules (PNs) are benign, well-limited melanocytic proliferations that can occur within congenital nevi, particularly larger ones. Although they may mimic melanoma clinically and histologically, PNs are characterized by a monomorphic, well-defined cell population with peripheral blending with the adjacent nevus cells, and a lack of severe atypias, numerous mitoses (in most instances), necrosis, or inflammation. They generally present at birth or early childhood, and even with cytological atypia, they do not undergo malignant transformation. The risk of malignancy associated with a large/giant congenital nevus is low but increases with size and the presence of multiple satellite lesions. Diagnostic tools, including immunohistochemistry and, in selected cases, molecular techniques such as CGH-array or RNA-seq, can help differentiate atypical PNs from melanoma. Awareness of this entity and its diverse histological features is crucial to avoid over-diagnosis of malignancy and unnecessary interventions. Here we report a case of atypical PNs in a giant congenital nevus and discuss the literature.

Open article ↗



2024-04-17 | Transcriptomic analysis of giant congenital melanocytic nevi across different anatomic sites

Abstract Background: Giant congenital melanocytic nevus (GCMN) is a skin disorder characterized by extensive abnormal proliferation and migration of melanocytes, which has the potential to be malignantly transformed into melanoma. Most studies have focused on revealing somatic mutation in GCMN. However, the specific alterations in gene expression across different anatomic sites of GCMN remain ambiguous. Methods: A total of 18 GCMNs including eight from the trunk, six from the head, and four from the extremities, as well as eight normal skin tissues were collected for transcriptome sequencing. Differential expression gene (DEG) analysis and a series of bioinformatics analyses were employed to explore the distinct expression pattern and involved pathways among different anatomic sites of GCMN. Results: A total of 258 (head), 1,472 (trunk), and 185 (extremities) site-specific DEGs were identified respectively, with a total of 368 up-regulated and 312 down-regulated DEGs in three tissues. Among them, ALB, CNTN2, GLI1, POU5F1 and CACNA1D were identified as core genes in head, as well as ERBB2, PPARA, VEGFA, FOS and IL1B in trunk, PRF1, STAT1, CXCR4, CD8A and CXCL8 in extremities, and SOX10, TYR, GRIN1, GRIA1 and PLP1 in all three tissues. Conclusion: This study mined the specific and common DEGs in the head, trunk, and extremities of GCMN and systematically explored the possible mechanism of action of these genes based on transcriptome sequencing data, which could provide insights for the research of GCMN and afford new therapeutic targets for GCMN patients.

Open article ↗



2022-09-09 | Association of novel MUC16, MAP3K15 and ABCA1 mutation with giant congenital melanocytic nevus

Giant congenital melanocytic nevus (GCMN) is the benign nevomelanocytic proliferation. Mutations in NRAS have been previously detected in GCMN, but mutations in BRAF are generally lacking in the Chinese population. Mutated genes in this disease can estimate the risk of malignant transformation in GCMN. Therefore, it is worth investigating the genetic information of GCMN.Here, we presented two cases of GCMN of the upper extremities. The clinical and histological data were analyzed. The whole exome sequencing (WES) was performed to investigate the mutational profile of peripheral venous blood (PB), normal skin (NS), small melanocytic nevus (SMN), deep penetrating and non-penetrating GCMN (dPGCMN and nPGCMN).We showed a reduction in the circumference of involved upper extremities in both patients. The clinical and histopathological data indicated the reduction of adipose tissue associated with the invasion of GCMN. The WES data revealed that MUC16, MAP3K15 and ABCA1 were novel potential candidate genes for the disease as well as biomarkers for predicting malignant transformation.The MUC16, MAP3K15 and ABCA1 may serve as novel biomarkers for predicting malignant transformation and targets for the diagnoses and therapy for the GCMN.

Open article ↗



small molecules
2026-06-23 | ID #138 Extramedullary Intradural Spinal Tumor in Infant with Neurocutaneous Melanosis

Abstract Neurocutaneous Melanosis (NCM) is a developmental disorder of melanocytic precursors resulting in an exceedingly rare disorder characterized by the presence of melanocytic nevi in the skin and leptomeninges. NCM diagnosis is traditionally made by the presence of large, pigmented congenital nevi in association with meningeal melanosis. The occurrence of intraspinal tumors are rarely reported. We describe the first case of a neonate diagnosed with NCM at birth who was concomitantly found to have a compressive, extramedullary, intradural NCM spinal tumor with leptomeningeal involvement. A full-term infant born at 39 weeks was noted at birth to have a giant melanocytic nevus with innumerable satellite nevi and diagnosed with NCM. MRI showed hyperintense areas on T1-weighted sequences consistent with melanin deposition in the brain and an enhancing mass in the spine from T10-T12 without hydrocephalus. After 3 weeks of life, the patient experienced obstructive hydrocephalus from leptomeningeal dissemination in the pons and upper cervical cord. A palliative VP shunt was placed. At 9 months of age, the patient presented with clinical signs of spinal cord dysfunction including mild axial hypotonia, increased peripheral tone, brisk suprapatellar reflexes, and difficulty bearing weight when lifted in vertical position. A T8-T12 laminoplasty for resection of the extramedullary spinal tumor was performed. Pathology revealed spindle cell neoplasm. At 4-months follow-up, there was no sign of recurrent mass in the spine, but leptomeningeal enhancement around the brain stem and cranial nerves remained. Exome sequencing of the resected tumor revealed two somatic cancer-associated sequence variants of NRAS and RAF1. Although the presence of an activating missense mutation in NRAS supports the diagnosis of NCM and has been previously described in NCM, RAF1 missense mutation is a novel variant identified in this patient. Novel insights from this case may provide important opportunities for targeted therapeutic intervention for infants with NCM.

Open article ↗



2026-05-03 | MC1R-Targeted Apoptotic Induction Followed by Melanocyte Stem Cell Transplantation: A Novel Therapeutic Strategy for Giant Congenital Melanocytic Nevus

Description: Giant Congenital Melanocytic Nevus (GCMN) is a rare congenital condition characterized by aberrant melanocyte proliferation affecting large areas of skin, including the face, with no current treatment achieving complete, safe resolution. This hypothesis proposes a three-stage targeted therapeutic strategy: Stage 1: A designed conjugate molecule (NDP-MSH + pH-sensitive linker + BH3 mimetic) selectively eliminates GCMN melanocytes via MC1R-mediated endocytosis and apoptotic induction — without affecting surrounding keratinocytes, nerve fibers, or vascular structures. Stage 2: Image-guided delivery using Line-field Confocal Optical Coherence Tomography (LC-OCT) ensures cellular-precision targeting at the dermal-epidermal junction. Stage 3: Autologous melanocyte stem cell transplantation repopulates the cleared niche with normally functioning melanocytes, restoring physiological pigmentation. This approach is supported by recent evidence confirming BCL2 overexpression in GCMN cells, and by established clinical outcomes in melanocyte transplantation for vitiligo

Open article ↗



2026-02-26 | Multilineage differentiation drives hamartoma formation in large-to-giant congenital melanocytic naevi: evidence for naevocyte multipotency.

Large-to-giant congenital melanocytic naevi (LGCMNs) often develop nodules that contain ectopic tissues (hamartomas), which are rarely observed in small-to-medium congenital melanocytic naevi (SMCMNs). The origin and mechanism of the hamartomas formed in LGCMNs remain unknown. To investigate the origin and mechanism of hamartoma formation in LGCMNs, and to evaluate the stemness and multipotency of LGCMNs. A total of 276 congenital melanocytic naevi (CMNs) of different sizes were included in this study. LGCMNs with diverse hamartomas were identified and analysed by histology and immunofluorescence. Whole-exome sequencing (WES) of matched healthy skin, LGCMN and hamartoma tissues assessed mutational overlap. RNA sequencing (RNAseq), immunohistochemistry and immunocytochemistry evaluated multipotency pathways and stem markers across CMN sizes. LGCMN and SMCMN cells were assayed for clonogenicity and induced to differentiate along osteogenic, chondrogenic, adipogenic and neurogenic lineages in vitro. Three-dimensional spheroid cultures and cell-derived xenograft (CDX) models tested LGCMN multilineage differentiation in vivo. Single-cell RNAseq (scRNAseq) of patient-derived hamartomas delineated intermediate differentiation states and active pathways. We found that LGCMN lesions harboured bone, cartilage, adipose and neural hamartomas with intermixed naevocytes. WES revealed 35-92% overlap of somatic mutations (including driver mutations) between LGCMN and hamartoma tissue, indicating a common origin. Immunofluorescence identified cells in hamartoma co-expressing lineage-specific and naevocyte markers, indicating intermediate differentiation states. RNAseq, immunohistochemistry and immunocytochemistry showed that LGCMNs were enriched for multipotency pathways and expressed higher levels of stem cell markers than SMCMNs. LGCMNs showed greater clonogenicity in vitro, and all LGCMNs robustly differentiated into osteocytes, chondrocytes, adipocytes and neuronal cells/astrocytes, whereas SMCMNs or healthy melanocytes largely failed. Intriguingly, in three-dimensional cultures and CDX models, LGCMNs were able to form lineage-specific hamartomas. scRNAseq identified intermediate differentiation clusters that co-expressed melanocytic and multilineage markers, confirming the transdifferentiation. Upregulation of neuroactive ligand-receptor signalling was identified as the common feature during differentiation. Hamartomas in LGCMNs originate from the LGCMN cells themselves, which undergo multipotent differentiation. LGCMNs have markedly greater stemness and multipotency than SMCMNs. Our data implicate the neuroactive ligand-receptor pathway in mediating LGCMN transdifferentiation. These findings shed light on LGCMN development and suggest that modulating differentiation pathways might offer new therapeutic approaches.

Open article ↗



2026-01-01 | Emerging Molecular Therapies for Large and Giant Congenital Melanocytic Nevi: Current Evidence and Translational Challenges

Large and giant congenital melanocytic nevi (L/GCMN) are rare mosaic disorders driven mainly by postzygotic activation of rat sarcoma viral oncogene homolog (RAS)/mitogen-activated protein kinase (MAPK) signaling. This narrative review compares emerging molecular therapies by model, biological effect, outcome, translational stage, and durability. Human evidence is limited to uncontrolled case reports and small series. Mitogen-activated protein kinase kinase (MEK) inhibitors have produced symptom relief, pigment lightening, and reduced hyperproliferative bulk, particularly in some fusiondriven lesions, but no clinical report has shown clearance of the congenital nevus or a durable response after withdrawal. An anaplastic lymphoma kinase inhibitor reduced lesion bulk in one genotypematched case. All other strategies remain preclinical. In primary cells, human explants, patient-derived xenografts, or animal models, allele-specific silencing of mutant neuroblastoma RAS viral oncogene homolog (NRAS), inhibition of B-cell lymphoma 2 (BCL2), phosphoinositide 3-kinase–protein kinase B (PI3K–AKT) blockade, immune activation, and histone deacetylase inhibition have produced effects ranging from pathway suppression to apoptosis or nevus-cell loss. These models are not directly comparable, and most findings await independent replication. Pigmentation, lesion dimensions, histologic markers, and mutant-cell burden measure different outcomes. Future studies should define the intended treatment goal, measure clinical and biological endpoints separately, and include follow-up after planned withdrawal. Local or intermittent delivery may reduce cumulative exposure in cutaneous L/GCMN. Combinations of complementary mechanisms warrant further preclinical study. Establishing whether treatment suppresses the nevus phenotype or removes nevus cells, at an exposure acceptable for children, is likely to matter more than adding molecular targets.

Open article ↗



2025-11-28 | Amelanotic melanoma of the central nervous system with systemic spread - imaging pitfalls and clues in a rare paediatric case with congenital melanocytic naevi.

Amelanotic melanoma involving the central nervous system (CNS) in association with congenital melanocytic naevi (CMN) is exceptionally rare and aggressive. Our literature review identified only two prior paediatric cases, reported in 1999 and 2021. To the best of our knowledge, this is the first reported paediatric case of CNS amelanotic melanoma with systemic metastases associated with CMN. We present a 2-year-old girl with CMN who developed an afebrile seizure, vomiting and neurological decline. Imaging revealed hydrocephalus, diffuse leptomeningeal enhancement, spinal cord compression and distant metastases. Histopathology confirmed metastatic amelanotic melanoma. She was treated with targeted therapy comprising trametinib and azacitidine, with a plan for immunotherapy (nivolumab and ipilimumab) after weaning off intravenous dexamethasone for cord compression. This case underscores the diagnostic challenge due to imaging similarities with other neoplastic, infectious and inflammatory pathologies. Given the aggressive nature and poor prognosis, a high index of suspicion should be raised for melanoma in patients with CMN and neurocutaneous melanosis who develop progressive neurological symptoms.

Open article ↗



cell therapies
2026-01-01 | Advances in the Treatment of Congenital Giant Nevi with Artificial Dermis

Congenital melanocytic nevus (CMN) is a common congenital pigmented skin lesion, and giant CMN remains challenging in reconstructive surgery because of the large defect after resection.Conventional approaches such as flaps and autologous skin grafting are limited by donor-site morbidity, multiple operations and obvious scar contracture.Artificial dermis, as a dermal substitute, provides a three-dimensional scaffold that promotes vascularization and dermal regeneration, and has been

Open article ↗



2024-03-10 | Superficial Temporal Artery Island Flap Combined With Laser Hair Removal for Inadequate Skin Expansion Following Tissue Expansion: A Case Report of Congenital Melanocytic Nevus of the Forehead in an Adult

Tissue expansion is a handy reconstructive technique for the head and neck region; however, its implementation requires careful planning and surgical experience. If tissue expansion is inadequate, forced closure results in wound tension and risks complications, such as postoperative deformity, wide scarring, and wound dehiscence. We report a case of adult forehead melanocytic nevus excision using a tissue expander (TE) where complications caused by insufficient tissue expansion were avoided by creating a flap using a dog ear. The patient was a male in his 20s who underwent surgery with a TE for a congenital melanocytic nevus sized 15 × 10 cm on the left forehead. Resection was performed by tissue expansion using two TEs; however, simple advancement flaps led to excessive wound tension, risk of elevation of the eyebrow on the affected side, and postoperative scarring. Hence, a superficial temporal artery fasciocutaneous island flap with left superficial temporal vessels as a pedicle was raised at the dog ear and moved to the site of strong tension, and the wound was closed without difficulty. Although postoperative laser hair removal was required, both the appearance and functional results were satisfactory. Using anatomical flaps obtained from the surroundings during tissue expansion helps avoid complications associated with forced wound closure.

Open article ↗



2023-10-30 | Reconstruction of a medium-sized congenital melanocytic nevus defect using a thin thoracodorsal artery perforator free flap: a case report

Congenital melanocytic nevus (CMN) is a benign condition that either is present at birth or develops in the first weeks of life. Surgical removal is typically performed to improve cosmetic appearance and reduce the risk of malignant transformation. In this report, we present the case of a 26-year-old woman with a medium-sized CMN on her left breast. The nevus measured 14×8 cm, and the patient desired a single-stage excision. However, this approach would result in a large skin defect that would be challenging to reconstruct using a local flap or skin graft. Moreover, it could potentially compromise the maintenance of natural sagging and the contour of the breast. Consequently, we opted to place a thin thoracodorsal artery perforator free flap following the removal of the CMN. The patient was satisfied with the overall surgical results. By utilizing this free flap for reconstruction, we successfully preserved the natural shape and contour of the breast without complications such as postoperative hypertrophic scarring or contracture at the recipient site.

Open article ↗



2022-05-01 | Keratinocyte Culture: Siriraj’s Experience

Objective: Cell-based therapy is gaining increasing prominence in medicine, where it has the potential to replace or repair damaged tissue using new engineered cells. Skin cell engineering, also known as keratinocyte culture or cultured epithelial autograft (CEA), is a promising field in cell-based therapy. CEA is now used in many parts of the world as an alternative treatment for some diseases that require large defects to be covered, such as severe and major burn patients and congenital melanocytic nevus. The use of CEA in conjunction with acellular skin substitution is rapidly expanding.Materials and Methods: This study is an initiative aimed at supporting the production and use of keratinocyte cultures at Siriraj Hospital. This is the first stage of developing sheet keratinocyte culture in vitro.Results: Our study yielded very promising results. As feeder cells, we used irradiated 3T3 murine fibroblasts, as per the standard protocol for keratinocyte culture. The growth duration was four weeks: 2 weeks for the 3T3 murine fibroblasts and 2 weeks for the keratinocytes. The keratinocytes grew rapidly and formed sheets with irradiated 3T3 murine fibroblasts. The retrieval of the cell sheets was straightforward thanks to the temperature-response cell culture dish and halo-ring cell recovery sheet. Flow cytometry revealed that the cells had a very high viability and purity. H&E staining revealed the sheets comprised two to four layers of stratified epithelial tissue.Conclusion: From this study, our method of manufacturing the CEA can offer a promising result. This can be use in the treatment which require large skin coverage. However, we aim to initiate animal and human trial phase next.

Open article ↗



2021-01-26 | Clinical Analysis of Cultured Epidermal Autograft (JACE) Transplantation for Giant Congenital Melanocytic Nevus

Cultured epidermal transplantation (JACE) is performed for giant congenital melanocytic nevus (GCMN), but there are few reports on its postoperative course and surgical content or indications. We aimed to investigate the postoperative course of GCMN patients undergoing cultured epidermal autograft transplantation and compare the outcomes between 2 nevus tissue resection methods.Twelve GCMN patients aged 0 months to 8 years and 9 months were included in this single-center case series study. Cultured epidermal autograft transplantation was performed at 19 sites of the patients' extremities and trunks, after excision of the nevus either by using an electric dermatome, which we initially used in 2017, or by curettage with a sharp spoon and use of a hydrosurgery system (Versajet), which we started performing in 2018. Univariate and multivariate analyses were performed for factors associated with postoperative hypertrophic scar formation.In all cases, >90% of the grafts survived, and the dark brown color of the nevus was reduced. Average postoperative observation period was 16.5 months. Hypertrophic scar formation was observed postoperatively at 9 wound sites out of the 12 sites with GCMN removed with a dermatome and at only 1 site with GCMN removed by curettage with use of a hydrosurgery system. In the univariate and multivariate analyses, hypertrophic scar formation was associated with age at surgery.In cultured epidermal autograft transplantation for GCMN, nevus tissue removal at an early age by curettage with use of a hydrosurgery system can provide good results while reducing complications, including recurrence and hypertrophic scar formation.

Open article ↗



antibodies
2025-11-25 | Epigenomic characterization and therapeutic challenges of melanoma arising in giant nevi in pediatric patients

BACKGROUND: Congenital giant melanocytic nevi (CGMN) are rare melanocytic proliferations present at birth, associated with an increased risk of pediatric malignant melanoma (MM). Melanomas arising within CGMN are uncommon but clinically aggressive, with diagnostic challenges due to overlapping histopathological features with benign proliferations. This case series explores the clinicopathologic, molecular, and therapeutic profiles of three pediatric patients with MM arising in CGMN. METHODS: An integrated analysis-including histopathology, immunohistochemistry, mutational profiling (NRAS, BRAF, PRKAR1A), copy number variation (CNV) analysis, and DNA methylation profiling using the classifier developed at the German Cancer Research Center (DFKZ) in Heidelberg-was performed on tumor and matched nevus samples. RESULTS: All tumors harbored MAPK pathway alterations, including NRAS Q61 mutations or BRAF fusions. DNA methylation profiling confirmed malignant transformation, while matched nevi clustered as melanocytoma with flat CNV profiles. Immunotherapy with checkpoint inhibitors (nivolumab ± ipilimumab) was used in all cases despite low PD-1/PD-L1 expression. However, therapeutic response was inconsistent, and two patients developed severe immune-related hepatitis requiring treatment discontinuation. Only one patient remains in remission. Epigenomic analyses revealed that benign and malignant components shared a close clustering pattern, suggesting a common cellular origin and patient-specific epigenetic imprinting. CONCLUSION: MM arising within CGMN poses diagnostic and therapeutic challenges. While molecular and epigenomic profiling supports accurate classification and understanding of disease biology, the role of immunotherapy remains uncertain-marked by reduced efficacy and significant immune-related toxicity. A multidisciplinary approach is essential to guide management and improve outcomes in this rare pediatric malignancy.

Open article ↗



2018-11-01 | RARE-03. CHARACTERISTICS OF PATIENTS WITH NEUROCUTANEOUS MELANOSIS: THE MSK EXPERIENCE FROM 2003–2018

The incidence of large congenital melanocytic nevi (LCMN) is 1/20,000 with 25% of children diagnosed with neurocutaneous melanocytosis (NCM), characterized by excessive proliferation of melanocytes in the leptomeninges and brain parenchyma. Specifically the disorder represents abnormal migration of melanocyte precursors due to abnormal melanin-producing genes in primitive leptomeningeal cells. While NCM can transform to melanoma, the molecular drivers involved in NCM related melanoma are different from the drivers in patients with non-NCM related melanoma. Children who become symptomatic from NCM may have a poor prognosis overall with 25–60% developing melanoma. While melanoma typically harbors mutations in the BRAF gene, NCM has a distinct molecular signature comprised primarily of mutations in the NRAS gene. We reviewed our institutional database from 2003–2018 and identified 47 patients with large congenital melanocytic nevi (LCMN) and NCM. Fifteen were female and 16/47 died. Five had molecular testing which revealed an NRAS mutation in the affected tissues. Four patients who developed melanoma, received targeted therapy including off label trametinib, nivolumab and/or ipilumumab. While none of these patient were longterm survivors, one patient lived for 12 months after receiving radiation therapy, nivolumab and ipilumumab. One patient with a VP shunt developed intraperitoneal melanoma, malignant ascites and subsequently died. CONCLUSIONS: While NCM which transforms to melanoma is typically fatal, new targeted therapies may offer prolonged survival. Further efforts to identify which patients are high risk are needed in an attempt to offer earlier treatment.

Open article ↗



2005-11-22 | Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma.

Glypican-3 (GPC3) mRNA and protein are expressed in >80% of human hepatocellular carcinomas (HCC) but not in normal tissues except for placenta and fetal liver. The oncofetal antigen GPC3 is a glycosylphosphatidyl inositol-anchored membrane protein and may be secreted. It is a novel tumor marker for human HCC: GPC3 protein was present in sera from 40-50% of HCC patients, but was not detected in sera from patients with liver cirrhosis or chronic hepatitis, or in sera from healthy individuals. alpha-Fetoprotein (AFP) and PIVKA-II (protein induced by vitamin K absence or antagonist-II), are well known major tumor markers for HCC. Generally, AFP shows high positivity for HCC but also high false-positivity in detection assays. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) is a recently described marker of HCC. Detection of AFP-L3 shows a much higher specificity than AFP, but a lower sensitivity. On the other hand, detection of PIVKA-II shows a lower false-positivity, but is not always sensitive enough to detect low levels secreted by small HCCs. There was no correlation between the three tumor markers, AFP, PIVKA-II, and GPC3 in terms of their presence in HCC cells. All three tumor markers showed similar positivity in patients with HCC, detecting 80% of patients with the disease. GPC3 is also a novel tumor marker for the diagnosis of human melanoma, especially in the early stages of the disease. Expression of GPC3 mRNA and protein was evident in tumor cells from >80% of patients with melanoma and melanocytic nevus, which is a common benign lesion. GPC3 protein was detected in sera from 40% (36/91) of melanoma patients, but not in sera from those with large congenital melanocytic nevus, or from healthy donors. Surprisingly, we detected serum GPC3 even in patients with stage 0, in situ melanoma. The positive detection rate of serum GPC3 at stage 0, I, and II (44.4%, 40.0%, 47.6%, respectively) was significantly higher than that of 5-S-cysteinyldopa, a well known tumor marker for melanoma (0.0%, 8.0%, and 10.0%, respectively). Interestingly, GPC3 was highly immunogenic in mice and elicited effective anti-tumor immunity with no evidence of autoimmunity. Thus, GPC3 is useful for diagnosis of HCC and melanoma and may also have a role in immunotherapy or tumor prevention. However, studies in humans are warranted.

Open article ↗



proteins
2026-01-06 | Melanomas and Mesenchymal Tumors Arising in Giant Congenital Melanocytic Nevi: Clinico-Pathological and Molecular Characterization of a Case Series.

Giant congenital melanocytic nevi (GCMN) are benign mosaic disorders that may give rise to various tumor types through incompletely understood mechanisms. We characterized a series of two melanomas and four mesenchymal tumors (two embryonal rhabdomyosarcomas, one small round cell sarcoma, one low-grade mesenchymal tumor) arising in GCMN. Median onset age was 3.5 years and 3 months for melanoma and mesenchymal tumor patients, respectively. Both melanoma patients succumbed within 27 months from diagnosis, whereas no patients progressed in the mesenchymal group (median follow-up 46 months). NRAS Q61, BRAF V600E mutation, and a novel in frame BIN1::BRAF fusion were detected in four, one, and one cases, respectively, with a higher variant allele frequency in the tumors compared with the matched GCMN. Copy number alterations and/or copy-neutral loss of heterozygosity were exclusively found in the tumors in all cases. An inactivating ASXL1 variant and an in-frame KDM5B::LPGAT1 fusion were identified in one melanoma; paternal disomy of 11p15.5 in both embryonal rhabdomyosarcomas. Mesenchymal tumors and melanomas showed distinct transcriptional profiles enriched in muscle and synapse organization and epidermal differentiation genes, respectively.

Open article ↗



2025-10-01 | Utility of Clinical and Dermoscopic Study of Cutaneous Nevi

Abstract Background: Dermoscopy is a noninvasive diagnostic tool that enhances the visualization of subsurface skin structures, enabling the differentiation of various types of nevi. Aims and Objectives: To assess the clinical features and dermoscopic patterns of cutaneous nevi. Materials and Methods: This cross-sectional study involved 100 patients presenting with nevi at a tertiary care dermatology outpatient clinic over 21 months. Demographic and clinical data were collected, and lesions were examined using a polarized, noncontact dermoscope (ILLUCO IDS-1100) connected to a smartphone. Dermoscopic images were analyzed for pattern types. Results: Participants ranged in age from 1 to 70 years (mean age 32.8 ± 14.3), with females making up 59% of the sample. The most common site of lesions was the cheek, followed by the back and chin. Compound melanocytic nevi were the most prevalent (57%), followed by junctional melanocytic nevi (14%), congenital melanocytic nevi (6%), and intradermal melanocytic nevi (6%). Less common types included Becker’s nevus, linear verrucous epidermal nevus, nevus depigmentosus, and port-wine stains. Dermoscopic analysis showed homogeneous patterns in 61% of cases, globular in 22%, reticular in 5%, cobblestone in 3%, structureless in 3%, papillary in 2%, blotchy in 2%, and dot patterns in 1%. Follicular openings were observed in 65% of lesions. Dermoscopic patterns varied according to the type of nevus. Conclusion: Dermoscopy facilitates rapid pattern recognition and enhances the accuracy of nevi classification. Additional large-scale, multicenter studies with histopathological correlation are recommended to confirm these findings.

Open article ↗



2024-11-28 | Dermatoscopic findings of giant congenital melanocytic nevus with palmoplantar involvement: A case report

Congenital melanocytic nevi (CMN) are melanocytic nevi defined by their presence at birth or in the first few weeks of life. A giant congenital melanocytic nevus (GCMN) is usually defined as a melanocytic lesion present at birth that will reach a diameter ≥20 cm in adulthood. Despite its rarity, this lesion is important because it may be associated with severe complications, such as malignant melanoma, which can affect the central nervous system (neurocutaneous melanosis) and can have a major psychosocial impact on the patient and his family due to its unsightly appearance. Herein, we present a case report of GCMN in an 18-year-old male involving the palms and soles.

Open article ↗



2024-09-02 | Title: Investigating Spontaneous Regression in Large Congenital Melanocytic Nevus: A Single-Cell Transcriptomic Study

Background Large congenital melanocytic nevus (LCMN) is a lifelong and potentially malignant skin melanocytic tumor. Case reports have documented spontaneous hypopigmentation of congenital melanocytic nevi, with histological evidence of immune cell infiltration in the lesions. Objective To explore the mechanism behind the spontaneous regression of LCMN. Methods Using Sanger sequencing and 10x Genomics single-cell RNA sequencing technology, we analyzed the genotype and cell population transformations during the spontaneous regression of LCMN. Results Our findings highlight the pivotal role of IFN-II in regressing LCMN by reversing immune evasion. IFN-II stimulates melanocytes, enhancing their antigen presentation function to recruit cytotoxic immune cells. Endothelial cells and fibroblasts further amplify the inflammatory response and help reconstruct the tumor microenvironment. The regressed LCMN displayed a marked reduction in melanocytes, increased immune cell infiltration, and remodeling of the tumor microenvironment, characterized by angiogenesis and fibroblast activity. Conclusion This study is the first to apply single-cell RNA sequencing technology to LCMN. Our unique sample provides novel insights into the tumor microenvironment of LCMN and its immune mechanisms, offering potential avenues for immunotherapy. Our findings suggest that IFN-II therapy, TIL therapy, and DC immunotherapy could be promising treatment options for LCMN, pending further validation in larger patient cohorts and transgenic animal models.

Open article ↗



2022-10-25 | OPN3 Regulates Melanogenesis in Human Congenital Melanocytic Nevus Cells through Functional Interaction with BRAFV600E.

OPN3, as a member of the opsin family, has various nonlight-dependent functions. Congenital melanocytic nevus (CMN) is a skin lesion with dark pigmentation that appears at birth and can be initiated by the BRAFV600E mutation in melanocytes. However, the role of OPN3 in BRAFV600E CMN cell melanogenesis has never been reported. In this study, we show that OPN3 acts as a negative regulator of melanin production by modulating BRAFV600E signaling in BRAFV600E CMN cells. Knocking down OPN3 expression can inhibit the BRAFV600E/extracellular signal‒regulated kinase signaling pathway and upregulate the expression of microcephaly-related transcription factors, tyrosinase, and TRP1 and TRP2, thus increasing melanin levels in BRAFV600E CMN cells. More remarkably, OPN3 and BRAFV600E were found to form a physical complex. Furthermore, a three-dimensional nevus model was used to further prove the negative regulatory effect of OPN3 on BRAFV600E CMN cell melanogenesis. Our study reveals a mechanism for OPN3-mediated melanogenesis in BRAFV600E CMN cells, and these results may lead to a more personalized and economically viable approach to treating BRAFV600E CMN.

Open article ↗



other
2026-06-23 | Mitotic Proliferative Nodule Within a Giant Congenital Nevus: One Case Report and Updated Review

Proliferative nodules (PNs) are benign, well-limited melanocytic proliferations that can occur within congenital nevi, particularly larger ones. Although they may mimic melanoma clinically and histologically, PNs are characterized by a monomorphic, well-defined cell population with peripheral blending with the adjacent nevus cells, and a lack of severe atypias, numerous mitoses (in most instances), necrosis, or inflammation. They generally present at birth or early childhood, and even with cytological atypia, they do not undergo malignant transformation. The risk of malignancy associated with a large/giant congenital nevus is low but increases with size and the presence of multiple satellite lesions. Diagnostic tools, including immunohistochemistry and, in selected cases, molecular techniques such as CGH-array or RNA-seq, can help differentiate atypical PNs from melanoma. Awareness of this entity and its diverse histological features is crucial to avoid over-diagnosis of malignancy and unnecessary interventions. Here we report a case of atypical PNs in a giant congenital nevus and discuss the literature.

Open article ↗



2024-04-17 | Transcriptomic analysis of giant congenital melanocytic nevi across different anatomic sites

Abstract Background: Giant congenital melanocytic nevus (GCMN) is a skin disorder characterized by extensive abnormal proliferation and migration of melanocytes, which has the potential to be malignantly transformed into melanoma. Most studies have focused on revealing somatic mutation in GCMN. However, the specific alterations in gene expression across different anatomic sites of GCMN remain ambiguous. Methods: A total of 18 GCMNs including eight from the trunk, six from the head, and four from the extremities, as well as eight normal skin tissues were collected for transcriptome sequencing. Differential expression gene (DEG) analysis and a series of bioinformatics analyses were employed to explore the distinct expression pattern and involved pathways among different anatomic sites of GCMN. Results: A total of 258 (head), 1,472 (trunk), and 185 (extremities) site-specific DEGs were identified respectively, with a total of 368 up-regulated and 312 down-regulated DEGs in three tissues. Among them, ALB, CNTN2, GLI1, POU5F1 and CACNA1D were identified as core genes in head, as well as ERBB2, PPARA, VEGFA, FOS and IL1B in trunk, PRF1, STAT1, CXCR4, CD8A and CXCL8 in extremities, and SOX10, TYR, GRIN1, GRIA1 and PLP1 in all three tissues. Conclusion: This study mined the specific and common DEGs in the head, trunk, and extremities of GCMN and systematically explored the possible mechanism of action of these genes based on transcriptome sequencing data, which could provide insights for the research of GCMN and afford new therapeutic targets for GCMN patients.

Open article ↗



2022-09-09 | Association of novel MUC16, MAP3K15 and ABCA1 mutation with giant congenital melanocytic nevus

Giant congenital melanocytic nevus (GCMN) is the benign nevomelanocytic proliferation. Mutations in NRAS have been previously detected in GCMN, but mutations in BRAF are generally lacking in the Chinese population. Mutated genes in this disease can estimate the risk of malignant transformation in GCMN. Therefore, it is worth investigating the genetic information of GCMN.Here, we presented two cases of GCMN of the upper extremities. The clinical and histological data were analyzed. The whole exome sequencing (WES) was performed to investigate the mutational profile of peripheral venous blood (PB), normal skin (NS), small melanocytic nevus (SMN), deep penetrating and non-penetrating GCMN (dPGCMN and nPGCMN).We showed a reduction in the circumference of involved upper extremities in both patients. The clinical and histopathological data indicated the reduction of adipose tissue associated with the invasion of GCMN. The WES data revealed that MUC16, MAP3K15 and ABCA1 were novel potential candidate genes for the disease as well as biomarkers for predicting malignant transformation.The MUC16, MAP3K15 and ABCA1 may serve as novel biomarkers for predicting malignant transformation and targets for the diagnoses and therapy for the GCMN.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

1 orphan drug designation for Large congenital melanocytic nevus.

1 orphan drug designation for Large congenital melanocytic nevus.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

Ulixertinib

—

FDA
2013-06-24

Phase II
Ongoing

BioMed Valley Discoveries, Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.